Profile data is unavailable for this security.
About the company
Ind Swift Limited is an India-based pharmaceutical manufacturing and marketing company. The Company operates in both domestic and export markets. It is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The Company is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. It operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The Company also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. It has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The Company also has five plants in India.
- Revenue in INR (TTM)5.02bn
- Net income in INR142.31m
- Incorporated1986
- Employees1.67k
- LocationInd Swift Ltd781, Industrial Area,Phase II,CHANDIGARH 160002IndiaIND
- Phone+91 1 724680800
- Fax+91 1 722652242
- Websitehttp://www.indswiftltd.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biofil Chemicals and Pharmaceuticals Ltd | 384.48m | 6.69m | 1.07bn | -- | 160.38 | -- | 97.77 | 2.80 | 0.4118 | 0.4118 | 23.91 | -- | -- | -- | -- | -- | -- | 2.86 | -- | 5.39 | 6.82 | 11.61 | 1.74 | 2.97 | -- | 27.03 | -- | -- | 34.19 | 19.43 | -19.76 | 3.55 | -51.09 | -- |
| Lasa Supergenerics Ltd | 1.17bn | -214.42m | 1.15bn | 89.00 | -- | -- | -- | 0.9841 | -4.28 | -4.28 | 23.30 | -- | -- | -- | -- | 13,128,270.00 | -- | -2.61 | -- | -3.75 | 29.74 | 32.34 | -18.35 | -3.67 | -- | -0.949 | -- | -- | -5.51 | -12.02 | -624.41 | -- | -- | -- |
| Zenith Drugs Ltd | -100.00bn | -100.00bn | 1.15bn | -- | -- | 5.09 | -- | -- | -- | -- | -- | 13.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8679 | -- | 0.5617 | -- | 24.95 | -- | 64.70 | -- | -- | -- |
| Ind Swift Ltd | 5.02bn | 142.31m | 1.19bn | 1.67k | 8.33 | -- | 2.87 | 0.2362 | 2.63 | 2.63 | 92.94 | -127.54 | 0.7705 | 3.66 | 3.91 | -- | 2.18 | -0.902 | 60.58 | -- | 44.02 | 45.72 | 2.83 | -1.44 | 0.8668 | 0.3401 | 3.14 | -- | 22.21 | 11.68 | -45.34 | 11.68 | 15.24 | -- |
| Sotac Pharmaceuticals Ltd | 579.83m | 44.96m | 1.35bn | 89.00 | 21.96 | 8.56 | 22.12 | 2.34 | 5.58 | 5.58 | 60.69 | 14.31 | -- | -- | -- | -- | -- | -- | -- | -- | 30.90 | -- | 7.75 | -- | 0.9968 | 8.62 | 0.4806 | -- | -20.74 | -- | 56.17 | -- | -- | -- |
| Aarey Drugs and Pharmaceuticals Ltd | 3.48bn | 42.19m | 1.40bn | 0.00 | 30.02 | -- | 24.49 | 0.4021 | 1.66 | 1.66 | 137.72 | -- | -- | -- | -- | -- | -- | 2.78 | -- | 5.84 | 4.17 | 3.66 | 1.21 | 1.52 | -- | 1.63 | -- | -- | -14.96 | 3.70 | -42.38 | -9.40 | 10.95 | -- |
| Krebs Biochemicals And Industries Ltd | 504.22m | -197.29m | 1.43bn | 210.00 | -- | -- | -- | 2.84 | -9.16 | -9.16 | 23.41 | -55.29 | 0.2856 | 0.606 | 41.52 | -- | -11.17 | -17.87 | -16.29 | -27.01 | 86.94 | 24.50 | -39.13 | -58.62 | 0.1237 | -3.30 | 2.61 | -- | -3.29 | 1.09 | 20.10 | -- | 16.76 | -- |
